Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib  in patients with EGFRm advanced NSCLC.

With the educational support of:

You may also be interested in:

The remaining challenges with neo-adjuvant immunotherapy in early-stage NSCLC

The optimal management of stage III NSCLC

Two good options for patients with stage III NSCLC

Tags:

poster